TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to study the efficacy and safety of the combination of TLK286
with cisplatin as first-line therapy for patients with locally advanced or metastatic
non-small cell lung cancer.